Mutual of America Capital Management LLC Trims Stake in Insulet Co. (NASDAQ:PODD)

Mutual of America Capital Management LLC lessened its holdings in Insulet Co. (NASDAQ:PODD) by 2.3% during the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 9,818 shares of the medical instruments supplier’s stock after selling 234 shares during the period. Mutual of America Capital Management LLC’s holdings in Insulet were worth $2,285,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. Wedmont Private Capital increased its stake in Insulet by 3.5% in the 3rd quarter. Wedmont Private Capital now owns 1,433 shares of the medical instruments supplier’s stock worth $326,000 after acquiring an additional 48 shares during the last quarter. OVERSEA CHINESE BANKING Corp Ltd increased its position in shares of Insulet by 4.7% in the third quarter. OVERSEA CHINESE BANKING Corp Ltd now owns 1,076 shares of the medical instruments supplier’s stock worth $250,000 after purchasing an additional 48 shares during the last quarter. Blue Trust Inc. raised its stake in Insulet by 84.1% in the third quarter. Blue Trust Inc. now owns 127 shares of the medical instruments supplier’s stock valued at $30,000 after purchasing an additional 58 shares in the last quarter. Sumitomo Mitsui DS Asset Management Company Ltd lifted its position in Insulet by 1.1% during the second quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 6,265 shares of the medical instruments supplier’s stock valued at $1,264,000 after purchasing an additional 66 shares during the last quarter. Finally, Greenleaf Trust grew its stake in Insulet by 4.2% in the 3rd quarter. Greenleaf Trust now owns 1,783 shares of the medical instruments supplier’s stock worth $415,000 after buying an additional 72 shares in the last quarter.

Insulet Price Performance

PODD stock opened at $262.93 on Monday. The stock has a market capitalization of $18.44 billion, a price-to-earnings ratio of 45.02, a PEG ratio of 4.01 and a beta of 1.22. The firm’s 50-day moving average price is $241.32 and its two-hundred day moving average price is $211.02. The company has a current ratio of 3.68, a quick ratio of 2.80 and a debt-to-equity ratio of 1.21. Insulet Co. has a 12-month low of $160.19 and a 12-month high of $279.40.

Analysts Set New Price Targets

Several research firms have recently weighed in on PODD. Raymond James raised their price objective on shares of Insulet from $213.00 to $260.00 and gave the company an “outperform” rating in a research report on Monday, October 14th. Barclays lifted their price target on Insulet from $220.00 to $234.00 and gave the stock an “equal weight” rating in a research note on Monday, November 11th. UBS Group increased their price objective on Insulet from $211.00 to $223.00 and gave the company a “neutral” rating in a research report on Friday, August 9th. Sanford C. Bernstein assumed coverage on Insulet in a research report on Wednesday, November 6th. They issued an “outperform” rating and a $300.00 target price for the company. Finally, Canaccord Genuity Group increased their price target on shares of Insulet from $236.00 to $269.00 and gave the company a “buy” rating in a research report on Wednesday, September 25th. Three research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $253.27.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.